Here's Your Chance to Invest in a Stock Named One of Time's "Best Inventions of 2022"

Biotricity (NASDAQ: $BTCY) is delivering innovative diagnostic and post-diagnostic solutions for chronic conditions and ​lifestyle improvement. And if the company's latest offering is an indication, then it looks like a $219B industry is about to change.

Biotricity has found an unprecedented opportunity for better heart disease treatment.

51.7 percent of adults have at least one chronic disease

86 percent of healthcare spendings are on chronic diseases

7 out of 10 top causes of death are chronic diseases

Heart Disease is the No. 1 Killer of Adults in the World

According to the CDC, heart disease is the leading cause of death in the United States.

Heart disease refers to "a range of conditions" affecting the heart, including:

Blood vessel disease, such as coronary artery disease
Irregular heartbeats (arrhythmias)
Heart problems you're born with (congenital heart defects)
Disease of the heart muscle
Heart valve disease
WHAT Is Biotricity?

What You Should Know

Biotricity is a medical technology company committed to improving healthcare by developing solutions that aid in chronic disease prevention and management. The company specializes in remote monitoring solutions for chronic illnesses and adjacent connected healthcare applications in the diagnostic and post-diagnostic markets, for both medical and consumer use markets.

In terms of R&D, Biotricity is focused on the preventative healthcare market with a vision of putting health management into the hands of the individual. Moreover, the company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.

The company's proprietary remote patient monitoring platform can be leveraged for various industries. Plans are underway to pipeline new solutions across a spectrum of health applications, including remote COPD monitoring, fetal monitoring, sleep apnea monitoring, and other chronic conditions.

Chart analysis and price targets

$BTCY has broken out of a long term downtrend on long term charts. With the long term analyst targets of 2.02 as the “low” and 7.88 as the “high” we are looking at a potential profit minimum of over 100% and high of 688% based on expert consensus.

Chart history shows that $BTCY has the tendency to have strong impulse moves, which sets us up for maximum profitability in minimum time. The downtrend that all biotechs have had over the past 10+ months has been broken, with higher highs on all time frames, from the hourly to the weekly chart, shaping for strong entry points currently. 

Bullish divergence on the 4 hour and weekly charts, showing incredible short swing and long hold potential
MACD Golden Crossover on 4 hour chart
20 ema on the verge of bullish crossing the 50 ema
Sitting at a quad top from the past 4 trading days, setting up for a strong impulse move on the sustainable volume the past 4 trading days


$1.30 - 31% potential profit (one week)

$1.54 - 54% potential profit (2+ weeks)

$1.99 - 99% potential profit (1+ month)

$3.39 - 239% potential profit (3+ months)

Biotricity's Looking to Curb Deaths From Heart Disease

It may be a relatively little-known stock, but Biotricity is working on comprehensive disease management for the no. 1 killer of adults in the world. In the US alone, there are an average of 1800 deaths from heart disease every day.

Every blue chip stock on the market started with an idea, identifying a demand, and following through with a product or service that changes the market, we have one that is truly changing lives at the same time.


Bioflux, the company's flagship device, is a high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient's ECG information.

Bioheart is a personal lifestyle solution that utilizes the validated technology from Bioflux for continuous collection across three channels of heart data.

Biocare (telemed and cardiac), a bridge of physician and patient consultation, is a HIPAA-compliant platform to streamline consultations and improve quality of care with visualized data for preventative lifestyle maintenance.

The Market's Hottest Biotech

$BTCY has become one of the hottest biotech’s on the market, and there is a mix of both stock and company catalysts that have our heart rates up as we dig in.

All accessible via your phone, with continuous monitoring that gives the patient real time data that can drastically improve, if not save their life. Continuous trinity of information to patient to doctor safeguards high risk heart patients, and gives awareness to at risk patients.

Biotricity's prioritization of R&D will bring continuous advances to the market with the ability to access data and monitor continuously. This will also help patients make lifestyle decisions that will improve the quality of their lives.

Stock Price Catalysts

60 percent gross margin (2022Q3)

$1.81m in revenue in 2022Q2, or a 143-percent increase YOY

400-percent upside from 52-week high with entire biotech sector exceeding performance projections

Cash balance up 600 percent from 2019 to end of fiscal year 2021

Rated "BUY" with targets: $2.02 (low) and $7.88 (high), or an outlook of 100 to 500 percent

Company & Product Catalysts

Logged 2 billionth heartbeat for Atrial Fibrillation (AFib) studies with Bioflux (huge milestone in stroke and heart disease R&D)
Global market for AFib expected to reach $26B by 2027 with CAGR of 13.2 percent
Biocare (telemed and cardiac), The bridge of physician and patient consultation, with HIPAA compliant platform and the streamlined process of time saving consultations and improved
The focus on Research and Development that Biotricity brings will bring continuous advances to the market with the ability to access data and monitor continuously and help patients make lifestyle decisions that will improve quality of life.
Heatbeat 3D

The Dream Team

Chairman, CEO, Founder
Dr. Waqaas Al-Siddiq, Phd

Waqaas, the founder of Biotricity, is a serial entrepreneur, a former investment advisor and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in various conferences such as IEEE and the National Communication Council.

VP of Engineering
Spencer Lowe

Spencer is an expert in wireless communication and has worked with the United States Department of Defense. His academic career was highlighted by various innovative projects and designs. His specialties are in the design and implementation of radio frequency, digital, analog, embedded software and PC software.

John Ayanoglou

John has over 25 years of accounting, finance, and operations experience, having previously served as CFO of several public companies and a regulated financial institution. As CFO of Equitable Group, Mr. Ayanoglou raised over $130 million of regulatory capital in common, preferred, and debenture offerings over successive transactions.

Amir Ali

Amir is a serial entrepreneur with over 20 years of experience in launching companies and producing innovative products, services, and solutions. Amir is sought after for his expertise in transforming R&D technologies into products based on market needs, commercializing products for volume production, and establishing global distribution channels across the world.

Looking for even more information?


Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage .We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Virtus Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers' works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer's communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Compensation: Pursuant to an agreement between Virtus Media LLC and Lifewater Media, Virtus Media LLC has been hired for a period beginning on 11/16/22 and ending after four business days to publicly disseminate information about (NASDAQ: BTCY) via digital communications. We have been paid twenty thousand USD via ACH Bank Transfer.